Alvotech (ALVO) announced that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar
- Alvotech price target lowered to $10 from $13 at UBS
- Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals
- Alvotech Reports Strong Turnaround in Financial Performance
- Alvotech’s Earnings Call: Growth Amid Challenges